BIO-Europe: Sweden's Alligator Bioscience is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward

blonca9
Nov 4, 2024
1 min read

CEO Søren Bregenholt describes this program, and why Alligator chose pancreatic cancer. Plus, he discusses CD40 x CEA(CAM5) and 4-1BB x 5T4 bispecifics the company is developing.

Brought to you by

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

BIO-Europe: Sweden's Alligator Bioscience is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight